Skip to search formSkip to main contentSkip to account menu

tegobuvir

National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

GS-9190

Broader (2)

PurinesPyridazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Preclinical Characterization of the Novel HCV NS3 Protease Inhibitor GS-9256
Background GS-9256 is an inhibitor of HCV NS3 protease with a macrocyclic structure and novel phosphinic acid pharmacophore… 
2015
2015
In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance.
2013
2013
Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451
ABSTRACT GS-9451 is a selective hepatitis C virus (HCV) NS3 protease inhibitor in development for the treatment of genotype 1… 
2012
2012
Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a.
2012
2012
Pharmacokinetic / Pharmacodynamic Predictors of Clinical Potency for 1 Hepatitis C Non-Nucleoside Polymerase and Protease Inhibitors 2 3
1 Hepatitis C Non-Nucleoside Polymerase and Protease Inhibitors 2 3 Authors: Micaela B. Reddy, Peter N. Morcos, Sophie Le Pogam… 
Highly Cited
2011
Highly Cited
2011
Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase
ABSTRACT GS-9190 (Tegobuvir) is a novel imidazopyridine inhibitor of hepatitis C virus (HCV) RNA replication in vitro and has… 
2011
2011
425 FOUR-WEEK TREATMENT WITH GS-9256 AND TEGOBUVIR (GS-9190), ± RBV ± PEG, RESULTS IN ENHANCED VIRAL SUPPRESSION ON FOLLOW-UP PEG/RBV THERAPY, IN GENOTYPI 1A/1B HCV PATIENTS
2011
2011
1211 EMERGENCE AND PERSISTENCE OF NS5B MUTATIONS FOLLOWING COMBINATION TREATMENT WITH TEGOBUVIR (GS-9190) PLUS STANDARD OF CARE-LONG-TERM FOLLOW-UP FROM THE PHASE IIB STUDY GS-US-196-0103
2011
2011
482 IN VITRO COMBINATION THERAPY WITH TEGOBUVIR (GS-9190) IS HIGHLY EFFICIENT IN CURING CELLS FROM HCV REPLICON AND IN DELAYING/PREVENTING THE DEVELOPMENT OF ANTIVIRAL RESISTANCE
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)